Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 12/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488740 | 0.90 | SLC34A1 (0.47) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3488991 | 0.88 | SLC34A1 (0.43) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3488535 | 0.84 | CDC7 (0.45) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3489022 | 0.84 | SLC34A1 (0.43) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3488169 | 0.84 | SLC34A1 (0.41) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3488824 | 0.81 | ALDH1A1 (0.36) | SLC34A1MAPK14PGRNR3C2ALDH1A1 | |
| SCHEMBL3490548 | 0.81 | ALDH1A1 (0.36) | SLC34A1MAPK14PGRNR3C2ALDH1A1 | |
| SCHEMBL3489948 | 0.80 | SLC34A1 (0.40) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3490298 | 0.79 | SLC34A1 (0.38) | SLC34A1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3488163 | 0.78 | PTGS1 (0.41) | SLC34A1PTGS2PGRNR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | SLC34A1 982/4885MAPK14 646/4885MAPK13 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.